Sickle cell disease (SCD) nephropathy and lower estimated glomerular filtration rate (eGFR) are risk factors for early mortality. Furthermore, rate of eGFR decline predicts progression to endstage renal disease in many clinical settings. However, factors predicting renal function decline in SCD are poorly documented. Using clinical, laboratory, genetic, and metabolomic data, we evaluated predictors of renal function decline in a longitudinal cohort of 288 adults (mean age 33.0 years). In 193 subjects with 5-year follow-up data, mean rate of eGFR decline was 2.35 mL/min/1.73 m 2 /year, nearly twice that of African American adults overall. Hyperfiltration was prevalent at baseline (61.1%), and 36.8% of subjects experienced rapid eGFR decline (≥3 mL/min/1.73 m 2 /year). Severe Hb genotype; proteinuria; higher platelet and reticulocyte counts, and systolic BP; and lower Hb level and BMI were associated with rapid decline. A risk scoring system was created using these 7 variables and was highly predictive of rapid eGFR decline, with odds of rapid decline increasing 1.635-fold for every point increment (P < 0.0001).
Renal findings in SCDN include hematuria, proteinuria, hyposthenuria, papillary necrosis, other renal tubular defects, and renal failure. Glomerular ischemia is thought to contribute pathophysiologically by promoting glomerular hyperfiltration, commencing in early childhood, leading to glomerular hypertrophy and intraglomerular hypertension. 9, 10 Secondary hemodynamic injury ultimately results in progressive renal failure from vascular dropout, fibrosis, and focal segmental glomerulosclerosis (FSGS). [11] [12] [13] SCDN is typically marked by proteinuria, with an eventual rise in serum creatinine, but other clinical signs, such as hyperfiltration and increasing anemia, may occur earlier. 5, 14, 15 Estimated GFR (eGFR) is a frequently used measure of SCDN but can overestimate true GFR due to prevalent hyperfiltration. While measured GFR (mGFR) is ideal, eGFR is often the only clinically available measurement. No consensus exists regarding the optimal GFR estimating equation in SCD, [16] [17] [18] though one study suggested the CKD-EPI equation is most accurate. 19 Nevertheless, worsening eGFR has been shown to be associated with decreased survival in SCD. 1 Additionally, a growing body of evidence suggests that the rate of annual GFR decline is predictive of progression to ESRD and death in the general population, [20] [21] [22] [23] and that a rapid rate of decline of approximately ≥3 mL/min/1.73 m 2 /year is a useful surrogate measure of clinically meaningful outcomes. 21, 24, 25 Previous studies have identified various other potential markers of SCDN. 1, 4, 11, 14, 19, [26] [27] [28] [29] For example, hemoglobinuria has been found to be associated with chronic kidney disease (CKD) and albuminuria, but the association of markers of hemolysis with SCDN still remains unclear. 28 Lactate dehydrogenase (LDH) was also associated with proteinuria and CKD in two studies 27, 28 but not with proteinuria in another study. 19 Hypertension was associated with proteinuria 30 but not mortality. 1 Hb level did not correlate with renal insufficiency in one study, 4 but other studies suggested a strong correlation. 1, 28 The G1 and G2 alleles of the APOL1 gene encoding apolipoprotein L-1 (ApoL1) are strongly associated with FSGS and hypertensive ESRD and are thought to underlie the higher rates of renal disease in African vs European Americans. [31] [32] [33] We recently identified these two variant alleles as risk factors for presence of SCDN as well. 30 Despite this intriguing association, bolstered by recent studies showing a correlation between the APOL1 risk alleles and varying degrees of proteinuria and CKD progression, 29, 30, 34 few studies have rigorously examined the rate of renal function decline in individuals with wild-type vs variant APOL1 alleles.
Recently, urine proteomic analysis has been used to identify biomarkers associated with CKD in SCD. 35, 36 Additionally, recent studies using metabolomic profiling in the general CKD literature have characterized metabolic changes at different stages of CKD and attempted to identify potential biomarkers of CKD progression. [37] [38] [39] [40] [41] However, the approach of plasma metabolomic profiling, which might yield disease-specific insights into CKD pathogenesis and progression, 38, 40 has not yet been applied to SCDN.
To increase knowledge about factors associated with progression of SCDN and thus risk of accelerated mortality, we evaluated a wide range of clinical, laboratory, genetic, and metabolomic factors for association with rate of eGFR decline in a longitudinal SCD cohort.
Understanding the factors associated with renal function decline in SCD is an essential step towards identification and testing of early therapeutic interventions.
| METHODS
This retrospective study was performed in 288 adults (age ≥ 18 at enrollment) with SCD, followed at Duke University Medical Center, with available DNA samples for APOL1 genotyping. The 288 subjects were enrolled in a previously well-described multicenter study of genetic factors associated with SCD complications. 1 Baseline data were obtained at enrollment in the original study, and chart review was performed to collect descriptive and clinical data from subsequent encounters. Follow-up laboratory data were collected using the data extraction tool DEDUCE (Duke Enterprise Data Unified Content Explorer). 42 Only data from nonemergent outpatient encounters were used in order to minimize the influence of acute illness on eGFR measurements, with the exception of the variable "peak creatinine" (highest serum creatinine from any follow-up encounter). eGFR was calculated using both the 
| Clinical and laboratory factors
Clinical and laboratory factors were assessed at baseline (ie, at enrollment) and are listed in Tables 1 and 2. Proteinuria and hemoglobinuria were defined as ≥1+ protein or blood on urine dipstick in the absence of hematuria, and hematuria as >5 red blood cells per high power field.
Baseline complete blood count values were an average of the 3 most recent steady-state measurements at enrollment. We reported mean values with SD for all continuous variables.
| APOL1 genotyping
APOL1 variants (SNPs rs73885319 and rs71785313) were genotyped as previously described, 30 using Taqman Predesigned Genotyping Assays (Applied Biosystems, Foster City, CA) and an ABI 9700 dual 384-well Geneamp polymerase chain reaction (PCR) system (Applied Biosystems). Genotyping and analysis was performed with an ABI Prism 7900 Sequence Detection System (Applied Biosystems).
| Metabolomic profiling
Metabolomic profiling was performed as part of another substudy, in which subjects were selected on the basis of availability of a plasma sample, renal function data, survival data, genome-wide association study (GWAS) data, and known hydroxyurea use and Hb F status. †
The units of eGFR, mL/min/1.73 m 2 , will be henceforth referred to as mL/min. 
| Statistical analysis
Linear regression was used to evaluate bivariate associations between baseline predictors and baseline eGFR, which approximated a normal distribution. Trajectories of eGFR decline were obtained from beta estimates of eGFR regressed on time (years) for each subject. The fit of each line was assessed using root-mean-square error (RMSE). Rapid rate of annual eGFR decline was defined as a slope ≥3 mL/min. 24, 25 Logistic regression was used to assess bivariate associations between baseline predictors and rapid eGFR decline, using baseline eGFR as a covariate. Age and sex were not used as covariates because they are included in eGFR calculations and were themselves confounded with many baseline predictors. Due to our previous work suggesting that the APOL1 risk variants had different functional effects, 47 the G1 and G2 variants were analyzed individually rather than combined into a single locus measure, employing an additive genetic model. Statistical analysis was performed using SAS version 9.4 (SAS Systems, Cary, NC).
Metabolomic data were analyzed for association with baseline eGFR and rapid eGFR decline using R (www.r-project.org). To reduce missingness, metabolites with <20% missing data were imputed using k-nearest neighbor averaging (R package impute). 48 Linear regression was used to test for association between baseline eGFR and each known metabolite; logistic regression was used for rapid eGFR decline. Permutation tests were performed resampling 100 000 times, and resulting P values <0.05 were deemed statistically significant. and laboratory values, and medical history were obtained by both interviews and review of medical records, using standardized case report forms. Demographic and baseline clinical characteristics of our cohort are described in Table 1 . The mean age at enrollment was 33 years; 53.1% were female. Hemoglobin genotype distribution was representative of our overall patient population.
Mean follow-up of renal outcomes was 7.4 AE4.2 years, and mean number of outpatient eGFR measurements was 25.6 AE25.1 per patient. To study the trajectory of eGFR decline, we identified 193 SCD subjects without baseline CKD and with a minimum of three outpatient eGFR measurements over a fixed 5-year follow-up from enrollment. Their baseline characteristics were similar to those of the original sample, except for the length of follow-up time, number of outpatient eGFR measurements, and baseline eGFR (Table 1) , all of which result from the subcohort selection criteria used. The difference in baseline eGFR disappears if subjects with baseline CKD are reincorporated into the subcohort.
| Endpoint definition and baseline associations
As our primary endpoint was decline in eGFR, we examined whether to use the MDRD or CKD-EPI method of GFR estimation. Mean baseline eGFR was 148.6 mL/min (by MDRD) 17 and 127.3 mL/min by CKD-EPI. 18 The prevalence of baseline hyperfiltration was 62.9% by MDRD and 56.9% by CKD-EPI. GFR estimations from the two equations correlated well for eGFRs in the low to normal range but diverged for eGFRs over~150 mL/min, with MDRD producing a wider range (Supporting Information Figure S1 ). Given the tendency of the MDRD equation to overestimate GFRs in the hyperfiltration range, as previously described, 16, 19 all further analyses used the CKD-EPI equation. Hyperfiltrators at baseline were younger than non-hyperfiltrators (mean age 26.3 vs 41.0, P < 0.0001), as expected. Nonetheless, hyperfiltration was prevalent in our baseline dataset well into adulthood ( Figure 1A ).
As has been demonstrated in other studies, baseline eGFR in our cohort was associated with several variables (Supporting Information   Table S1 ). Of note, more severe Hb genotypes (Hb SS and Sβ 0 -thalassemia) were associated with higher baseline eGFR and a higher percentage of hyperfiltrators compared to Hb SC and Sβ + -thalassemia (P = 0.023 and P = 0.0001, respectively). The presence of proteinuria, hemoglobinuria, antihypertensive use, and higher SBP and DBP were associated with lower baseline eGFR, while higher Hb level, platelet count, and total bilirubin were associated with higher baseline eGFR (Supporting Information Table S1 ). APOL1 G1 and G2 minor allele frequencies (0.24 and 0.14, respectively) were consistent with previous reports 30 and did not vary with age. Using an additive genetic model, the APOL1 G1 risk allele was associated with lower baseline eGFR (P = 0.014), but the G2 risk allele was not.
Metabolomic profiling of 107 subjects with a mean baseline eGFR similar to the overall sample (n = 288) revealed plasma levels of 47 known metabolites to be associated with baseline eGFR (permutation P < 0.05; Supporting Information Using a previously described organ system severity score of SCD phenotypic severity (Supporting Information Table S1 ), 1, 50 we found that baseline eGFR varied inversely with disease severity (P < 0.0001) ( Figure 1B) . Pulmonary dysfunction and leg ulcers drove this negative association (Supporting Information Table S1 ). Kidney dysfunction was not assessed as an independent predictor given its overlap with the outcome of interest.
3.3 | Clinical and laboratory factors associated with rapid eGFR decline
As described above and in Severe Hb genotype, presence of proteinuria, higher platelet and reticulocyte counts, and higher SBP at baseline all increased the odds of rapid decline (Table 2 ). Higher Hb level and BMI decreased the odds of rapid decline. Higher overall organ system severity score was associated with rapid decline, but individual components were not.
Higher peak creatinine also increased the odds of rapid decline (P = 0.017). Other variables, including age (in decades), hydroxyurea use, antihypertensive use, chronic transfusion therapy, stroke, ACS, HCV infection, total bilirubin, DBP, and APOL1 G1 and G2 risk alleles,
were not associated with rapid decline.
| Metabolites associated with rapid eGFR decline
Among subjects with metabolomic profiles, 75 met criteria for inclusion in our 5-year trajectory analysis, 32 did not have 5 years of follow-up data, and 3 were excluded due to baseline eGFR <60 mL/min.
Among the 75 analyzed, the average annual eGFR decline was B, Mean baseline eGFR decreases with increasing disease severity, reflected by the baseline organ system severity score (P < .0001). C, Percentage of subjects with rapid eGFR decline increases with increasing baseline risk score (P < .0001). This scoring system was additive, ranging from 0 to 7, with one point each given for each of the following dichotomized baseline variables: severe hemoglobin genotype, presence of proteinuria, or, for continuous variables, if the subject's measurements were either above the mean levels in our cohort. The risk score was derived from a multivariate model using a backwards selection strategy with all significant bivariate predictors of rapid eGFR decline. Each risk factor was weighted equally, and risk scores of 5-7 were combined into one risk category due to sample size. This risk score correlated with the odds of rapid eGFR decline implicated in the pathogenesis of endothelial dysfunction and CKD 
| DISCUSSION

| Rate of eGFR decline is a meaningful predictor in SCDN
This is one of the first studies to examine the trajectory of renal function decline in adults with SCD. In our cohort, the rate of annual eGFR decline in subjects without CKD at baseline was 1.85× that of the general African-American population. 25 Furthermore, since eGFR equations may underestimate mGFR declines, 53 our findings may be a conservative estimate of the steep trajectory of true GFR decline in SCD. 53 A recent study of 41 Hb SS subjects found an even higher annual rate of mean mGFR decline (3.2 AE2.83 mL/min). 14 Remarkably, our SCD subjects without CKD had a rate of eGFR decline similar to African Americans with CKD (2.23 vs~2 mL/min respectively). 54 Our eight subjects with baseline CKD had an even higher, although not statistically different, rate of decline (5.05 mL/min). We expect that the rate of GFR decline may provide a meaningful predictor of progressive renal function decline in SCD, as it does in type 1 diabetes. Among markers of hemolysis, only hemoglobinuria was associated with lower baseline eGFR; bilirubin and LDH were not (Table 2) , suggesting that severity of hemolysis does not determine baseline renal function. Similarly, higher platelet count, a potential marker of inflammation, was associated with higher baseline eGFR, but WBC was not.
In light of the theory that hemolysis leads to inflammation-induced vascular damage and endothelial activation, causing end-organ damage such as renal dysfunction, 56 our finding that higher bilirubin and platelet count were associated with higher baseline eGFR was counterintuitive. However, this correlation may be confounded, as hemolysis and hyperfiltration are both more common in more severe Hb genotypes. Thus, hemolysis may be simultaneously associated with renal damage and higher eGFR. 43, 57 Moreover, another study found no association between hemolytic index and survival, 1 suggesting that mechanisms protecting against oxidative damage, rather than the extent of hemolysis, may be the determining factor in end-organ damage.
Inheritance of the APOL1 G1 risk allele predicted a lower baseline eGFR in comparison to wild-type APOL1, consistent with known associations of APOL1 G1 with CKD and proteinuria in SCD, and genetic modulators of SCD severity. 29 Nevertheless, it remains unclear how APOL1 G1 contributes to renal dysfunction. Our finding that the APOL1 G1 and G2 risk alleles were not associated with rate of eGFR and quinolinic acid) were associated with rapid eGFR decline (P = .025 and .046, respectively). Box and whiskers plots were used, with whiskers representing 5th-95th percentile and dots representing outliers decline shows that more investigation into the function of APOL1 is needed, and that cross-sectional associations cannot be extrapolated into conclusions about disease progression. Moreover, in light of recent investigation into composite genetic risk profiles predicting CKD progression, 29 our null finding suggests that the relationship between APOL1 risk alleles and eGFR decline may be more complex and that there may exist additional genetic risk factors that modulate the effect of APOL1 on renal function in SCD.
| Associations with rapid eGFR decline
At baseline, our subjects had a mean baseline eGFR of 134.3 mL/min, and 61.1% had eGFRs in the hyperfiltration range. Among subjects without CKD at baseline, multiple baseline factors influenced the odds of having rapid eGFR decline ( Table 2 ). Disease severity, characterized
by Hb genotype and the organ system severity score, was strongly associated with rapid eGFR decline, as well baseline eGFR. Indeed, elevated tricuspid regurgitant jet velocity and proteinuria have been found to be closely associated in several studies. 3, 58, 59 Only six individuals in our cohort (five with Hb SS and one with
Hb Sβ + -thalassemia) with baseline eGFR >60 mL/min developed CKD within 5 years. These subjects were on average older than the overall cohort (age 44.0 vs 33.0 years) and started with a lower baseline eGFR (94.7 vs 127.3 mL/min). The average rate of eGFR decline for these patients was dramatically higher (8.55 AE4.23 mL/min). Unfortunately, due to the limited sample meeting CKD criteria, we were unable to identify factors associated with development of CKD in these subjects. Future studies of progression to CKD and ESRD will likely require either a much longer study duration or enrollment of select patients with identifiable renal dysfunction or other risk factors at baseline. Nevertheless, it remains clear that decreased renal function is associated with accelerated mortality in SCD.
1,2,5
Hyperfiltration is considered to be an early stage of SCDN. In our study, baseline hyperfiltrators had a higher average rate of eGFR decline compared to nonhyperfiltrators (2.92 vs 1.44 mL/min; P = 0.018). Nonetheless, hyperfiltration was not significantly associated with our dichotomized outcome of rapid eGFR decline (P = 0.160), although our 5 year follow-up time may not have captured a longer term effect of hyperfiltration on renal function. Furthermore, our linear models make it difficult to capture the complex trajectory of GFR in SCD, as GFR rises in the initial decades of life due to hyperfiltration, then subsequently declines.
While some factors, such as Hb level, proteinuria and SBP, have been previously identified as markers of longitudinal renal function decline, 14 the effects of others, such as BMI and peak creatinine, are not well understood. In the general population, obesity and metabolic syndrome are generally considered risk factors for CKD, progression of renal disease, and ESRD. 60, 61 However, the association in SCD of higher BMI with survival in CKD constitutes a "risk factor paradox." 62, 63 While obesity increases atherogenesis, inflammation, and oxidative stress, causing moderately increased mortality from atherosclerotic events, low BMI, as a proxy for malnutrition and coexistent diseases, may exert an even stronger influence on mortality. Thus, the association between higher BMI and decreased odds of rapid eGFR decline in SCD could be explained by less severe SCD phenotypes having a less hypermetabolic state; however, we found no association between BMI and disease severity score. Therefore, high BMI may represent a protective effect of good nutritional status on renal function in a chronically ill population.
Finally, in subjects without CKD at baseline, rapid eGFR decline was associated with higher final creatinine at the end of the 5-year follow-up period, suggesting that rate of eGFR decline can be considered a meaningful marker of progressive nephropathy in SCD. The fact that rapid decliners experienced on average a rise in creatinine over the follow-up period from 0.74 to 0.973 mg/dL supports a common concern that a "normal" creatinine value of 1.0 mg/dL may represent CKD in a patient with SCD. Moreover, peak creatinine was associated with increased odds of rapid eGFR decline and likely reflects the lasting effect of acute kidney injury (AKI) on chronic renal function, raising further concerns about how to prevent and manage AKI in SCD.
| Identifying new markers of SCDN and progression using metabolomic and risk profiling
Metabolomic profiling in a subset of subjects revealed that 47 of 179 known measured metabolites correlated with baseline eGFR and thus may serve as biomarkers for early renal dysfunction (Supporting Information Table S2 ). 37, [39] [40] [41] 45, 46, 49 Symmetric dimethylarginine (SDMA), the metabolite with the most significant baseline association, is a structural isomer of ADMA, thought to be potentially more sensitive than serum creatinine in detecting early renal dysfunction. 49, 64, 65 Indeed, SDMA was more strongly associated with baseline eGFR than serum creatinine. SDMA may also promote vascular dysfunction by reducing endothelial NO synthesis by limiting L-arginine availability to NO synthase, 64 thus potentially contributing more broadly to SCD vasculopathy.
Metabolites may also serve as better markers of nonglomerular renal dysfunction. Rhee et al. identified nine metabolites that reflect non-GFR renal function 40 ; four (citrulline, kynurenic acid, cis-aconitate, and isocitric acid) were also associated (P < 0.05) with baseline eGFR in our cohort, with an additional metabolite (L-kynurenine) trending towards significance (P = 0.057). Kynurenic acid and citrulline are markers of tubular secretion and renal metabolism, respectively.
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Another metabolite, indoleacetic acid, was negatively associated with eGFR, in agreement with previous studies, including the Atherosclerosis Risk in Communities (ARIC) study, in which a one-SD increase corresponded to 14.2 mL/min decrease in eGFR in African Americans. 39, 49 Interestingly, only ADMA and quinolinic acid were found to significantly correlate with rapid eGFR decline, with ADMA showing the strongest association. ADMA is mainly eliminated through hydrolytic degradation to dimethylamine and L-citrulline by renal dimethylarginine dimethylaminohydrolase (DDAH) 51, 66 ; only~20% is renally secreted. Reduced DDAH due to chronic renal injury can lead to early accumulation of both plasma ADMA and citrulline. In contrast, serum creatinine rises late in renal dysfunction due to hypersecretion by the proximal tubules. ADMA has also previously been shown to be an independent predictor of CKD progression in other populations. 37, 66 Thus, our results, together with previous literature, suggest that metabolomic data may provide more sensitive detection of both early and progressive renal dysfunction than currently available clinical laboratory tests. While we did not include metabolomic variables in our risk score due to the small sample size, it will be important to incorporate metabolomic data into future SCDN risk prediction modeling.
Our risk score is the first model to use routine clinical and laboratory data to predict the trajectory of renal function decline in SCD.
The odds of rapid eGFR decline increased with each point increment in the score, demonstrating that basic clinical and laboratory data can be used to risk stratify SCD patients' likelihood of developing nephropathy, and that a risk score may be helpful for stratifying subjects in future clinical trials investigating sickle nephropathy-related outcomes.
| Study limitations and summary
While future prospective studies of GFR decline could benefit from direct measurement of GFR, this would likely limit the number of measurements that could be collected to calculate an accurate trajectory.
Our analysis, utilizing an average of 13.2 outpatient eGFR measurements per subject, may thus more accurately estimate eGFR trajectory than using only sparsely collected mGFR (eg, at only baseline and follow-up).
Although severe Hb genotype was associated with higher mean baseline eGFR and greater odds of rapid eGFR decline, the relationship may be confounded by the fact that subjects with more severe Hb genotypes were younger (P < 0.0001) and more likely to have had hyperfiltration physiology at baseline (P = 0.0001). To explore this, we forced an age-matched comparison of Hb SS/Sβ 0 -thalassemia vs SC/Sβ + -thalassemia subjects and found no significant difference in baseline eGFR or odds of rapid decline, although the smaller sample size of this subset reduced our power to detect significant differences.
Nevertheless, this finding argues that the pathophysiology of SCDN may be similar in all SCD genotypes and therefore needs further examination.
In our study, proteinuria was assessed only by dipstick at study enrollment. Since a reading of ≥1+ is stipulated by the manufacturer of the test to indicate ≥30 mg/dL albumin, we used the 1+ measurement as our criterion for proteinuria. 67 Future studies would likely benefit from use of more precisely measured albumin/creatinine ratios.
In addition, we did not quantify the extent of exposures to treat- Finally, our risk score utilized cutoffs derived from the study cohort, and mean values for these measurements may vary in other populations. We also tried calculating the risk score using potentially more clinically relevant cutoffs of a platelet count of >450 × 10 6 /μL, reticulocyte count >300 × 10 6 /μL, SBP >125 mmHg, Hb level < 9 g/ dL and BMI <24 kg/m 2 . Encouragingly, altering the cutoffs did not change the predictive ability of the risk score. Ideally, our risk score will be tested in a prospective manner and incorporated into future clinical studies to determine whether treatments such as hydroxyurea and ACE inhibitors/ARBs can modify the trajectory of renal function decline in risk-stratified SCD cohorts.
In order to optimally design clinical studies of potential therapeutic interventions, investigators need a predictive model to identify patients at greatest risk of progressive renal function decline. Our study represents one of the most comprehensive evaluations of the trajectory of eGFR decline in a longitudinal adult SCD cohort to date, and we have identified factors strongly associated with rapid eGFR decline. Identifying early markers of SCDN and interventions for slowing the rate of GFR decline may have a dramatic impact on morbidity and mortality associated with SCDN, especially given the strong link between renal function and SCD mortality. 
